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Abstract
Objective—We examined whether six patient-provider communication behaviors directly 
affected the intraocular pressure (IOP) of glaucoma patients or whether patient medication 
adherence and eye drop technique mediated the relationship between self-efficacy, 
communication, and IOP.
Methods—During an 8-month, longitudinal study of 279 glaucoma patients and 15 providers, 
two office visits were videotape-recorded, transcribed, and coded for six patient-provider 
communication behaviors. Medication adherence was measured electronically and IOP was 
extracted from medical records. We ran generalized estimating equations to examine the direct 
effects of communication on IOP and used bootstrapping to test whether medication adherence 
and eye drop technique mediated the effect of communication on IOP.
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Results—Provider education about medication adherence (B = −0.50, p < 0.05) and inclusion of 
patient input into the treatment plan (B = −0.35, p < 0.05) predicted improved IOP. There was no 
evidence of significant mediation.
Conclusion—The positive effects of provider education and provider inclusion of patient input 
in the treatment plan were not mediated by adherence and eye drop technique.
Practice Implications—Providers should educate glaucoma patients about the importance of 
medication adherence and include patient input into their treatment plan.
Keywords
Glaucoma; Patient-provider communication; Medication adherence; Eye drop technique; 
Mediation analysis
1. Introduction
Glaucoma is the leading cause of irreversible blindness worldwide [1–3]. Over the next 35 
years, the global prevalence of glaucoma is projected to nearly double from 60 million to 
111.8 million patients [2], and a concomitant increase in glaucoma-associated blindness is 
likely unless patients receive and adhere to treatment. Topical glaucoma medications (i.e., 
eye drops) are commonly used to treat glaucoma and slow disease progression by lowering 
intraocular pressure (IOP); lowering IOP is the only intervention that has been shown to 
reduce vision loss in glaucoma [4,5]. However, patients are unlikely to experience the 
clinical benefits of their glaucoma medications if they: (1) are non-adherent to their 
medication regimen and (2) do not instill their eye drops correctly [6–9].
Street and colleagues posit that patient-provider communication can improve a clinical 
outcome like IOP directly as well as indirectly via increased patient engagement in self-care 
skills [10,11]. Glaucoma is an ideal condition in which to examine whether self-care skills 
(e.g., medication adherence and eye drop technique) mediate the effects of patient-provider 
communication on clinical outcomes for two reasons. First, there is great variability in 
patients’ medication-taking behaviors and taking medications properly is associated with 
better-controlled IOP [6–9,12]. Specifically, non-adherence rates range from 40 to 72% 
[6,7,13,14], and approximately half of glaucoma patients demonstrate incorrect eye drop 
technique [15–18]. Second, there is an association between patient-provider communication 
and glaucoma patients’ medication adherence and their eye drop instillation technique [17–
21]. Although previous studies have provided piecemeal links between communication, 
medication-taking behaviors and skills, and IOP; no studies have examined whether 
communication-related changes in patients’ medication-taking behaviors translates to 
improved clinical outcomes.
Both patient-provider communication and self-efficacy are important correlates of 
medication-taking behaviors [22]. More patient question-asking during medical visits, a 
component of patient activation, is associated with improved adherence to glaucoma 
medications [20,23] as well as better adherence and outcomes in other diseases [24,25]. In 
addition to patient question-asking, provider education about adherence is associated with 
better adherence in glaucoma [20] and other diseases like diabetes and asthma [26]. Because 
Carpenter et al. Page 2













glaucoma is an asymptomatic disease and patients may not notice any direct benefits when 
they take their medications, positive reinforcement and encouragement to take medications 
from providers may be important for improving adherence and patient outcomes [27]; 
however, these relationships have not been formally examined in glaucoma. Many patients 
are unaware that they use their eye drops incorrectly [15,16,18], and provider education 
about how to use eye drops is associated with better patient technique [17,18]. Additionally, 
provider inclusion of patient input in the treatment plan is associated with better clinical 
outcomes for diabetes patients [28,29] and has been posited as important for glaucoma 
patients [30]. Last, medication self-efficacy is associated with better adherence and better 
clinical outcomes for glaucoma patients [8] and patients with diabetes [31].
Building upon prior research, our objective was to apply Street’s model of communication 
[10,11] to examine the direct and indirect effects of patient-provider communication and 
self-efficacy on glaucoma patient IOP. We hypothesized that more frequent patient-provider 
communication and higher patient self-efficacy would indirectly improve IOP through better 
patient medication adherence and improved eye drop technique (Fig. 1). In terms of 
communication, we specifically examined whether more patient question-asking, more 
provider education about adherence and eye drop installation, more instances of provider 
encouragement and positive reinforcement for patients to take medications, and more 
frequent provider inclusion of patient input in the treatment plan were associated with better 
patient medication adherence, eye drop technique, and IOP.
2. Methods
2.1. Participants and procedures
We collected data for this multisite cohort study between 2009 and 2012. Providers from 6 
ophthalmology practices (2 private offices and 4 academic ophthalmology departments) 
from five distinct geographical regions participated in the study. Providers were told that the 
goal of the study was to learn about communication during glaucoma visits. Fifteen of the 
16 providers approached to participate in the study agreed to participate. This study was 
approved by the Institutional Review Boards at the University of North Carolina, Duke 
University, Emory University, and the University of Utah. All patients and providers gave 
written informed consent.
Providers completed a demographic questionnaire and clinic staff referred potentially 
eligible patients to a research assistant, who explained to patients that the purpose of the 
study was to improve health services provided in clinics. Eligible patients: (1) were ≥18 
years of age; (2) spoke English; (3) were glaucoma or glaucoma suspect patients; and (4) 
were mentally competent as determined by the Mental Status Questionnaire [32]. Ineligible 
patients were thanked and given $5. Eligible patients were enrolled and had their office visit 
videotape-recorded. Videotapes were kept and the patient was followed for the 8-month 
study period if the patient was either: (a) newly-diagnosed with glaucoma and received a 
new prescription for glaucoma medications or (b) was already taking glaucoma medications.
Participants had their medical visits videotape-recorded at two visits (baseline and a 4–6-
week follow-up). Immediately after their medical visits, a research assistant interviewed 
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patients in a private examination room and videotaped their eye drop administration. Patient 
medication adherence was electronically monitored over the 8-month study period using a 
Medication Events Monitoring System (MEMS 6 SmartCap; MWV Healthcare, Richmond, 
VA, USA). Patients received $20 at each visit.
2.2. Measures
The videotapes from the medical visits were deidentified and transcribed verbatim. The 
transcripts were reviewed by a research assistant who met twice a month with the 
investigators to develop a study codebook that contained the coding categories and rules. 
Three independent coders then used this codebook to code the transcripts for the patient-
provider communication behaviors listed in Table 1.
Over the course of the study, the three coders coded 25 of the same transcripts and met 
monthly to discuss discrepancies. Inter-rater correlations were used to assess intercoder 
reliability. Inter-rater reliability for the variables ranged from 0.75 to 1.0. If there was not 
enough variability to calculate reliability then we calculated percent agreement between the 
coders; percent agreement was 0.72 to 1.00 for these variables.
2.2.1. Patient question-asking about glaucoma medications—The glaucoma 
medication question-asking coding categories were developed using the patient question-
asking literature [33–35] and ophthalmologists’ input. After the original categories were 
developed and defined, patient questions were reviewed and the categories were further 
refined with input from the principal investigator and the research team. As a result, 
patients’ medication-related questions were classified into six areas: (a) general information 
about glaucoma medications, including the name, strength, and side effects; (b) information 
about the medication regimen, such as dosing, which eye(s) to instill the medication, and 
frequency of use; (c) how to administer the medication, including questions about how to 
instill eye drops and procedures for instilling multiple medications (e.g., time between 
drops); (d) cost or supply of the medication; (e) information about the purpose or importance 
of using glaucoma medications and adherence strategies; and (f) other medication questions. 
A question-asking summary score was then created by adding together the total number of 
medication questions the patient asked at the baseline and 4–6-week follow-up visit.
2.2.2. Provider communication behaviors—For each visit, coders recorded whether 
the provider: (1) educated about adherence and adherence strategies; (2) educated about eye 
drop instillation; (3) encouraged the patient to take their medications; (4) gave the patient 
positive reinforcement to take their medications; and (5) included patient input into the 
glaucoma treatment plan. Results were then summarized across both visits and coded as: 0 = 
provider did this at neither visit, 1 = provider did this at one visit, and 2 = provider did this 
at both visits.
2.2.3. Self-efficacy—Immediately after the 4–6-week follow-up medical visit, patients 
completed a 35-item, validated, glaucoma medication self-efficacy questionnaire [36]. The 
questionnaire possesses two scales: (1) 14 items that assess confidence in carrying out 
specific tasks to use eye drops correctly (i.e., eye drop task self-efficacy), including 
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squeezing the bottle, getting the right number of drops into the eye, and not touching the eye 
with the bottle; and (2) 21 items that assess confidence in overcoming adherence-related 
barriers (i.e., adherence-related barriers self-efficacy), such as being able to take medications 
when travelling or when they cost a lot of money. Response options ranged from 1 = ‘not at 
all confident’ to 3 = ‘very confident.’ Items were summed for each scale and ranged from 14 
to 42 for eye drop task self-efficacy (Cronbach α = 0.84) and 21 to 63 for adherence-related 
barriers self-efficacy (Cronbach α = 0.92). Higher scores indicated greater self-efficacy.
2.2.4. Patient eye drop technique—After the 8-month medical visit, a trained research 
assistant asked patients to use a bottle of artificial tears to instill a single drop onto their eye 
as they normally would at home. If the patient normally instilled drops in both eyes, he/she 
was asked to administer a drop onto the right eye. Otherwise, the patient was asked to instill 
the eye drop into the eye that he/she normally uses for glaucoma medications. Patients’ eye 
drop technique was video-tape recorded.
A trained coder then watched each eye drop technique videotape and used a checklist to 
evaluate the number of steps each patient performed correctly. The checklist was developed 
with input from the ophthalmologists on the study team and was informed by the literature 
on improving the effectiveness of topically applied drops [37–42]. The following steps were 
coded as “yes,” “no,” or “unclear”: (a) able to squeeze the bottle to produce a single drop, 
(b) instills a single drop onto eye, and (c) does not touch bottle tip to eye or face. An eye 
drop technique score was then calculated by adding together the number of steps the patient 
performed correctly. If any of the three steps were unclear, the patient’s summary score was 
not calculated.
2.2.5. Medication adherence—Medication adherence over the 8-month (or 240-day) 
study period was measured using electronically-recorded data from the MEMS caps system. 
The percentage of correct doses the patient took each day was calculated using the following 
formula: number of doses taken/ number of prescribed doses for each day. We then took the 
average of the daily percentage of correct doses taken each day across the 240-day period. 
For example, if the patient was prescribed a once daily medication and opened the MEMS 
bottle one time each day over the 240-day period, then the patient’s adherence was 100%. If 
the patient was prescribed more than one glaucoma medication, then an overall adherence 
variable was created by adding together the subject’s adherence for each glaucoma 
medication and dividing it by the total number of glaucoma medications. Adherence ranged 
from 0 to 100%, with higher scores indicating a higher percentage of doses taken each day.
2.2.6. Intraocular pressure—We extracted intraocular pressure (IOP) measurements 
from each patient’s medical record at both the baseline and 8-month follow-up visit. For 
both time points, a mean IOP variable was calculated by averaging the IOP across both eyes. 
Change in IOP over the 8-month period was then assessed by calculating the difference in 
mean IOP. Negative values indicated that IOP improved over the 8-month period.
2.2.7. Sociodemographic characteristics—Patients reported their age (in years), 
gender, and race. Race was measured as a categorical variable (White, African American, 
Asian, Native American, and Hispanic) and then dichotomized to African American and 
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non-African American. We also recorded whether the patient was prescribed glaucoma 
medication for the first time. On the provider questionnaire, providers reported their age, 
gender, and race. Provider race was measured as a categorical variable (White, African 
American, Asian, Native American, and Hispanic).
2.3. Data analysis
We used SAS Version 9.3 (Cary, NC) to perform all analyses. We used descriptive statistics 
to characterize the sample and then ran a generalized estimating equation (GEE) to explore 
the direct effects of patient-provider communication and self-efficacy on IOP. We set the a 
priori significance level at α = 0.05. Specifically, the model examined whether the patient-
provider communication variables and self-efficacy were associated with change in IOP. 
The model controlled for: provider age and gender; patient age, gender, race, and years of 
education; whether the patient was new to glaucoma medications; and patient baseline IOP. 
Provider race was not included as a control variable because we only had one non-White 
physician.
We then used a bootstrapping approach [44,45] to run two mediation models to explore 
whether patient-provider communication and self-efficacy had indirect effects on IOP. In the 
first mediation model, we examined medication adherence as the mediator; whereas, in the 
second model, eye drop technique was the mediator. We chose to run two separate 
mediation models because 95 participants had missing eye drop technique scores due to 
blocking the video camera during their technique assessment or having videos that were not 
focused enough to clearly assess technique. Each mediation model controlled for: baseline 
IOP; patient gender, and whether the patient was new to glaucoma medications. We used 
bias-corrected 95% confidence intervals to determine whether the point estimates for each 




Eighty-six percent (n = 279) of eligible patients participated in the study and completed the 
baseline visit. Final 8-month IOP values were missing for 31 patients; 21 who were lost to 
follow-up and 10 due to missing or illegible medical chart entries. Those without IOP values 
at the 8-month follow-up visit were more likely to be male (Pearson χ2 = 4.82, df = 1, p < 
0.05), less adherent (t(246) = −3.15, p < 0.01), and have better eye drop technique (t(182) = 
2.24, p < 0.05) than those who had 8-month IOP values. Table 2 presents the demographic 
and clinical characteristics of patients for whom we had 8-month IOP values.
Ten of the fifteen (67%) providers were male. Fourteen providers were White and one was 
African American. Provider age ranged from 26 to 66 years (mean 40.8 years, SD = 11.7 
years). Eighty percent (12) of providers were glaucoma specialists. The average years since 
graduation from medical school was 12.2 years (SD = 11.4 years, range = 1–38 years).
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3.2. Direct effects of self-efficacy and patient-provider communication on IOP
Table 3 presents the GEE results examining whether patient-provider communication and 
self-efficacy had direct effects on change in IOP over the 8-month study period. The GEE 
revealed that provider education about medication adherence and provider inclusion of 
patient input into the treatment plan both predicted a significant decrease in IOP. Male 
gender and being new to glaucoma medications were both associated with a greater decrease 
in IOP.
3.3. Indirect effects of patient-provider communication on IOP
Figs. 2 and 3 present the mediation analysis results. As shown in Fig. 2, adherence-related 
barriers self-efficacy and positive reinforcement from the provider to take medications were 
both significantly associated with greater medication adherence. Fig. 3 shows neither self-
efficacy nor any of the patient-provider communication variables were significantly 
associated with better eye drop technique. Table 4 shows that neither medication adherence 
nor eye drop technique significantly mediated the effect of communication or self-efficacy 
on patient IOP.
4. Discussion and conclusion
4.1. Discussion
This is the first article to explore whether medication adherence and eye drop technique 
mediated the effects of self-efficacy and patient-provider communication on the IOP of 
glaucoma patients. Based on prior studies and Street’s conceptual model linking 
communication to health outcomes [10,11], we had hypothesized that medication adherence 
and eye drop technique would mediate the relationship between self-efficacy and patient-
provider communication on IOP. Although provider education about medication adherence 
and provider inclusion of patient input into the treatment plan both predicted lower IOP at 8-
month follow-up; contrary to our hypothesis, we did not find evidence of significant 
mediation.
Provider inclusion of patient input in the treatment plan predicted a significant decrease in 
IOP. Previous studies with diabetes patients have also reported that inclusion of patient input 
in the treatment plan was associated with better clinical outcomes [28,29]. We had 
anticipated that the effects of including patient input on IOP would be mediated through 
improved medication-taking behaviors (e.g., adherence and technique), but inclusion of 
patient input in the treatment plan was not significantly associated with either of these 
variables. It is possible that including patient input in the treatment plan could affect 
different intermediate variables, such as patient commitment to treatment, motivation to 
adhere, or outcome expectations [10,11]. Because outcome expectations have been 
associated with better short-term medication adherence in glaucoma patients [46]; testing 
more complex mediation models in which including patient input leads to more positive 
outcome expectations for medications, which then improves medication adherence and 
ultimately decreases IOP is warranted. Alternatively, providers who include patient input 
may switch patients to more aggressive therapies, which may more effectively lower their 
IOP without affecting the patients’ medication adherence. As it seems unlikely that 
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including patient input in the treatment plan would have a direct effect on IOP, future 
studies should examine whether commitment to treatment, motivation to adhere, outcome 
expectations, or changes to the medication regimen do, in fact, mediate the relationship 
between including patient input in the treatment regimen and patient IOP.
Provider education about adherence and adherence strategies also was associated with 
improved patient IOP at 8-month follow-up; however, the effect was not mediated by 
medication adherence or eye drop technique. These findings are perplexing, since improved 
adherence seems like the most logical mediator between adherence education and IOP. It 
may be that patients in our sample perceived provider education about adherence as 
demonstrative of the provider’s overall concern for the patient’s well-being. Thus, a variable 
such as rapport, may have mediated the effect of adherence education on IOP. Alternatively, 
if providers were educating about adherence in a way that was not relevant to patients, that 
could potentially explain why education was unrelated to adherence in our sample. Future 
studies should examine whether providing adherence education that is more tailored to each 
patient’s adherence-related barriers predicts better adherence and clinical outcomes for 
glaucoma patients.
Adherence-related barriers self-efficacy was associated with greater medication adherence, 
but the increases in adherence did not translate to improved IOP at 8 months. Interestingly, 
previous analyses from these data found that both adherence-related barriers self-efficacy 
and provider education about how to administer drops were associated with better 
medication adherence at 60 days [23]. Because periodic retraining has been associated with 
better medication behaviors for conditions like asthma [47,48], it is possible that the 
beneficial effects of adherence education and technique education may deteriorate over time 
or that education about medications may need to adapt to patients’ changing circumstances. 
Future studies should investigate how often medication education is needed in order to 
maintain improvements in medication adherence and promote greater patient confidence to 
take medications correctly.
We were surprised that neither patient-provider communication nor eye drop task self-
efficacy was associated with better eye drop technique. Because using eye drops involves 
both knowledge and skill, it may be that more hands-on forms of education and repeated 
practice sessions are necessary to improve patients’ eye drop technique. Alternatively, 
patients’ techniques may improve immediately after receiving education but then deteriorate 
over a short period of time. Thus, our data collection time points may have been spaced too 
far apart to detect the beneficial effects of patient-provider communication on eye drop 
technique.
Other factors may have caused variation in IOP and may partially explain why we did not 
find evidence of significant mediation in our sample. For example, IOP can vary throughout 
the day (diurnal variation) and we were unable to capture some of this fluctuation since we 
only measured IOP one time at each office visit [49]. Although other studies have been able 
to assess glaucoma progression without accounting for diurnal variation [6,50], future 
studies should attempt to schedule each participant’s baseline and follow-up visits at 
approximately the same time of day in order to control for this important factor. Also, we 
Carpenter et al. Page 8













were unable to account for several other variables that could be associated with changes in 
IOP, including changes to the medication regimen, the presence of other medications that 
could affect IOP (e.g., beta blockers), and whether the patient had other IOP-lowering 
treatments, such as surgery. Future studies should include these variables as covariates in 
regression models. Additionally, future research should consider investigating whether 
medication adherence and eye drop technique mediate the relationship between 
communication and other clinical outcomes, such as changes to the optic nerve that can be 
measured with optical coherence tomography (OCT).
4.1.1. Limitations—This study has several limitations and results should be interpreted 
with caution. First, study staff did not track the characteristics of patients who declined to 
speak with the research assistant, so we could not calculate a patient participation rate or 
estimate the effects of selection bias. Moreover, patients who were missing 8-month IOP 
values were demographically different from patients who had IOP values; thus, our results 
may not generalize to the larger population of glaucoma patients. Second, providers and 
patients both knew the visit was being recorded, but they did not know the study hypotheses. 
Even if there was a Hawthorne effect, it was likely small, as patient-provider communication 
behaviors occurred infrequently. Third, as noted above, our clinical outcome variable, IOP, 
can be influenced by a number of other factors, including the time of day the IOP was 
measured and whether changes were made to the patient’s medication regimen, which we 
did not control for in these analyses. Our ability to detect mediating relationships was also 
limited by the weak association between medication adherence and eye drop technique with 
IOP. Furthermore, having a large number of unclear technique videotapes resulted in 
missing eye drop technique scores for 95 patients; which limited our power to detect 
whether eye drop technique significantly mediated the relationship between self-efficacy, 
communication, and IOP.
Lastly, we quantified communication behaviors in order to include them in GEE and 
mediation models. Accounting for the quality of communication could have explained 
additional variance in medication-taking behaviors and clinical outcomes and may be 
equally, if not more important, for patient outcomes. For example, educating about eye drop 
technique on two separate occasions may not result in improved eye drop technique if the 
provider’s instructions were confusing to the patient. Frequency of education may also fail 
to yield an effect on behavioral outcomes like medication adherence and eye drop technique 
if they are delivered generically and do not apply to a patient’s circumstances. For example, 
patients who have arthritis may not be able to squeeze the bottle to produce a single drop. In 
these cases, generic education about how to instill eye drops would not help those patients 
address the problem of squeezing the bottle; additional education and provision of aides to 
help instill drops may be necessary in those situations. Thus, future studies should examine 
both the quality and quantity of communication in order to make recommendations about 
optimal timing and content of educational messages.
4.2. Conclusion
We found that including patient input in the treatment regimen led to a significant decrease 
in IOP. The exact mechanisms through which including patient input resulted in improved 
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IOP are unknown but should be considered for future studies. Adherence education from 
providers was also associated with better IOP at 8-month follow-up. Greater adherence-
related barriers self-efficacy and positive reinforcement from providers to take medications 
were each associated with better patient medication adherence, although medication 
adherence did not act as a mediator between these variables and IOP.
4.3. Practice implications
Our findings demonstrate that provider communication is important to improving behavioral 
and clinical outcomes for glaucoma patients. Providers should give patients positive 
reinforcement to take medications since this behavior was associated with better adherence 
to glaucoma medications. Providers should also work with patients to increase their 
adherence-related barriers self-efficacy, as this also increases patients’ medication 
adherence. Providers should also educate patients about adherence and include patient input 
into the treatment plan, since engaging in these behaviors can lead to improvements in IOP.
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Conceptual model showing the potential direct and indirect effects of medication-related 
communication on glaucoma patient intraocular pressure.
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Modeling the indirect effects of adherence-related barriers self-efficacy and patient-provider 
communication on patient intraocular pressure (n = 223). Note: Model controlled for 
baseline IOP; patient gender, and whether the patient was new to glaucoma medications 
relationships. Dashed lines indicate insignificant relationships and solid lines indicate 
significant relationships; *p < 0.05; **p < 0.01; ***p < 0.001.
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Modeling the indirect effects of eye drop task self-efficacy and patient-provider 
communication on patient intraocular pressure (n = 172). Note: Model controlled for 
baseline IOP; patient gender, and whether the patient was new to glaucoma medications 
relationships. Dashed lines indicate insignificant relationships.
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Table 1
Codebook definitions and example quotations from transcripts.
Codebook variable and definition Example quotations from transcript text
Patient question-asking about glaucoma medications “Now does, do the drops reverse the damage or do they just slow it, or?”
Whether the patient asks one or more questions about 
their glaucoma medications or using eye drops, 
including how to administer eye drops, the medication 
regimen, side effects, cost or supply, adherence 
strategies, purpose, and importance of medications
“How often will I have to take those?”
“Those drops don’t affect your sleep does it?”
“Does it make a difference if you take if you use your drops say uh a few - thirty 
minutes before bedtime or right at bedtime? ”
Provider educates about medication adherence and/or 
adherence strategies Whether the provider educates the 
patient about adherence and adherence strategies, 
missed doses, and/or extra doses taken
“It is good to match taking these eye drops with something that you do already, like 
when you take out your contacts at night.”
Provider educates about eye drop instillation Whether 
the provider educates the patient about how to use eye 
drops correctly
“When we have you put in eye drops, we recommend that you wash your hands 
before you do it. Keep a real clean area. Don’t, you know, start, I don’t know - in the 
bottom of your kitchen sink or something. I tell people that if you bring your chin up 
and keep your eyes kind of flat and look up, you have a better aim, ok, and you have 
taken drops before.”
Provider encourages the patient to take medications “You should really use the eye drops every night.”
Whether the provider expressed encouragement for the 
patient to take their glaucoma medications
Provider gives positive reinforcement to take 
medications
“If you take your medications regularly, then your vision should stay fine.”
Whether the provider reinforces that medications are 
linked to positive outcomes
Provider includes patient input in treatment plan Example 1:
“Are you okay with taking the drops for the next month to see if we can reduce your 
intraocular pressure?”
Whether provider solicits patient input about whether 
they want to initiate or change their glaucoma 
medication regimen
Example 2:
Provider- “We had you taking Travatan last time is that right?”
Patient- “Uh yes.”
Provider- “And um … And we switched you back to Xalatan right?”
Patient- “Right.”
Provider- “Which one do you prefer? Can you tell the difference?”
Patient- “I can’t really tell the difference. Uh I know I was getting better results 
before um from the Xalatan.”
Provider- “Ok.”
Example 3:
Provider- “So the effect of the Latisse is a little stronger than this for growing lashes. 
Another option would be to switch you to Lumigan. So could you use Latisse? Yes 
you can. Um another option would be to switch you from the Latanoprost to 
Lumigan. Lumigan is literally the same drug that is Latisse. It’s used for glaucoma. It 
makes your lashes grow like crazy.”
Patient- “Like can we do that so I won’t have to use Latisse? Since I have to take the 
drops anyway. I’d much rather do that.”
Provider- “So the one thing with that is it has a little- I think a little bit higher risk of 
side effects around the eye. So let’s talk about that again. It can make the skin around 
your eye a little bit darker. It can make the blue part of your eye a little bit more 
brown. Um so otherwise I think it’s fine. If you’re up for that I think it’s fine.”
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Table 2
Patient sample characteristics (n = 248).
Characteristic N(%) or Mean(SD)
Sociodemographic
  Age (range: 25–93) 66.00 (12.6)
  Years of education (range: 5–26) 15.12 (3.5)
Male 107 (43.1)
Race
  African American 83 (33.5)
  White 153 (61.7)
  Other 12 (4.8)
Clinical
  Patient new to glaucoma medications 45 (18.1)
  Patient baseline IOP (mm Hg) (range: 7.0–47.5) 16.17 (4.7)
  Medication adherence (range: 6.6–100) 76.30 (23.2)
  Eye drop technique score (range: 0–3) 2.04 (0.6)
  Change in IOP from baseline to 8-month follow-up (mm Hg) (range: −35.0 to 27.5) −0.83 (5.0)
  Patient-provider communication
  Total number of patient questions about glaucoma medications (range: 0–17) 2.50(3.0)
Provider educates about medication adherence
  Neither visit 176 (71.0)
  1 visit 66 (26.6)
  Both visits 6 (2.4)
Provider educates about eye drop technique
  Neither visit 206 (83.1)
  1 visit 42 (16.9)
  Both visits 0 (0.0)
Provider encourages patient to take medications
  Neither visit 169 (68.1)
  1 visit 69 (27.8)
  Both visits 10 (4.0)
Provider provides positive reinforcement to take medications
  Neither visit 144 (58.1)
  1 visit 85 (34.3)
  Both visits 19 (7.7)
Provider includes patient input into treatment regimen
  Neither visit 202 (81.5)
  1 visit 39 (15.7)
  Both visits 7 (2.8)
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Table 3
Linear generalized estimating equation predicting change in patient intraocular pressure (IOP) at 8-month 
follow-up (N = 246).
Independent variables Beta (SE)
Total number of patient questions about glaucoma medications 0.12 (0.16)
Provider educates about medication adherence −0.50 (0.24)*
Provider educates about eye drop technique −0.26 (0.23)
Provider encourages patient to take medications 0.15 (0.15)
Provider provides positive reinforcement to take medications 0.07 (0.18)
Provider includes patient input into treatment regimen −0.35 (0.15)*
Adherence-related barriers self-efficacy −0.04 (0.25)
Eye drop task self-efficacy −0.11 (0.36)
Provider age 0.12 (0.16)
Provider gender 0.11 (0.13)
Patient age −0.70 (0.45)
Patient years of education 0.28 (0.31)
Patient gender 0.53 (0.20)**
Patient race −0.29 (0.41)
Patient new to glaucoma medications −0.79 (0.30)**
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Table 4
Indirect effects of patient-provider communication variables and self-efficacy on glaucoma patients’ 
intraocular pressure.
Indirect effect Point estimate (SE) Bias-corrected 95% confidence interval
Medication adherence (n = 223)
Adherence-related barriers self-efficacy 0.375 (0.71) −0.092 0.196
Patient asks medication questions 0.001 (0.03) −0.020 0.121
Provider educates about adherence strategies −0.003 (0.02) −0.087 0.028
Provider encourages patient to take medications 0.007(0.03) −0.020 0.102
Provider provides positive reinforcement 0.034 (0.07) −0.082 0.191
Provider includes patient input −0.011 (0.03) −0.139 0.020
Eye drop technique (n = 172)
Eye drop task self-efficacy −0.014 (0.06) −0.184 0.066
Patient asks medication questions 0.073 (0.07) −0.008 0.298
Provider educates about eye drop instillation 0.007 (0.05) −0.063 0.137
Provider encourages patient to take medications −0.009 (0.04) −0.120 0.050
Provider provides positive reinforcement 0.026 (0.05) −0.036 0.202
Provider includes patient input 0.006 (0.05) −0.064 0.135
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